ReviewClinical endocrinology2022
Approach to androgen excess in women: Clinical and biochemical insights.
Review in Clinical endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women.Clinical endocrinology · 2025Guideline
- Where are we in the diagnosis and treatment of hirsutism? A narrative review.Reviews in endocrine & metabolic disorders · 2026Review
- Dual case insights shaping a new protocol for post-menopausal hirsutism.JCEM case reports · 2026Article
- Review
- Mediating Effect of Sleep Quality on the Association Between Psychological Stress and Acne Vulgaris in Chinese College Students: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- THBS1: a biomarker for PCOS and its role in pathogenesis via the PI3K/AKT signaling pathway.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- An Update on the Role of Androgens and Androgen Receptor in Triple-Negative Breast Cancer.Cells · 2026Review
- Unraveling the Complexity of Polycystic Ovary Syndrome: Biomarkers for Diagnosis, Prognosis, and Treatment.Current pharmaceutical design · 2026Review
- The Intricate Puzzle of Adrenocortical Tumors: Revisitation of Two Old Cases of Virilizing Adrenocortical Neoplasia with Contradictory Diagnostic and Histopathological Findings and Opposite Conclusions.Life (Basel, Switzerland) · 2025Article
- Serum norethisterone (NET) levels in NET-enanthate (NET-EN) injectable contraception users substantially interfere with testosterone immunoassay measurements and confound interpretation of biological outcomes.Contraception and reproductive medicine · 2025Article
- Signs of Potential Androgen Excess Across the Lifespan in a US-based Digital Cohort Study.The Journal of clinical endocrinology and metabolism · 2025Article
- "Who and how to screen for endogenous hypercortisolism among young women presenting with clinical hyperandrogenism and/or menstrual abnormalities ".Journal of endocrinological investigation · 2025Review
- Severity of Hirsutism and Its Correlation With Hyperandrogenism: A Cross-Sectional Study in Erbil City.Cureus · 2025Article
- Cardiometabolic Aspects of Congenital Adrenal Hyperplasia.Endocrine reviews · 2025Review
- Hyperandrogenism in polycystic ovary syndrome and adrenal hyperplasia: finding differences to make a specific diagnosis.Archives of gynecology and obstetrics · 2025Review
- Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO).Frontiers in cardiovascular medicine · 2025Review
- Rare Conditions of Hyperandrogenism Through Lifespan: A Case Series.Case reports in endocrinology · 2025Article
- Review
- Circulating adrenal and gonadal steroid hormones heterogeneity in active young males and the contribution of 11-oxy androgens.Scientific reports · 2024Article
- Prevalence and Clinical Management of Adrenal Tumour-Related Hyperandrogenism: A Narrative Review.Life (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen excess in women typically presents clinically with hirsutism, acne or androgenic alopecia. In the vast majority of cases, the underlying aetiology is polycystic ovary syndrome (PCOS), a common chronic condition that affects up to 10% of all women. Identification of women with non-PCOS pathology within large cohorts of patients presenting with androgen excess represents a diagnostic challenge for the endocrinologist, and rare pathology including nonclassic congenital adrenal hyperplasia, severe insulin resistance syndromes, Cushing's disease or androgen-secreting tumours of the ovary or adrenal gland may be missed in the absence of a pragmatic screening approach. Detailed clinical history, physical examination and biochemical phenotyping are critical in risk-stratifying women who are at the highest risk of non-PCOS disorders. Red flag features such as rapid onset symptoms, overt virilization, postmenopausal onset or severe biochemical disturbances should prompt investigations for underlying neoplastic pathology, including dynamic testing and imaging where appropriate. This review will outline a proposed diagnostic approach to androgen excess in women, including an introduction to androgen metabolism and provision of a suggested algorithmic strategy to identify non-PCOS pathology according to clinical and biochemical phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.